Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT
- Registration Number
- NCT02779959
- Brief Summary
Headache is a common presenting complaint to the emergency department accounting for 1-2% of patient visits. Of these headaches, approximately 90% are migraine, tension headache, or combined presentations. The most commonly used migraine therapy in the ED is intravenous prochlorperazine, but its administration requires close nursing observation, a bed, and the insertion of an intravenous catheter. Buccal prochlorperazine represents an alternative form of delivery that enables rapid achievement of therapeutic blood levels and may lead to symptom resolution. In a randomized, controlled, prospective study,the investigators plan to assess the efficacy of buccal versus intravenous prochlorperazine for the initial emergency department treatment of migraine headaches.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 80
- Patients between 18-65 years of age evaluated in the emergency department at Harbor-UCLA with migraine headache as defined by the Headache Classification Committee of the International Headache Society. (Patients must have had at least one prior similar headache, with or without nausea, vomiting, aura, photophobia, or phonophobia).
- Only subjects able to consent to treatment will be included.
Patients with the following conditions:
- pregnancy
- breastfeeding
- fever greater or equal to 100.4 degrees
- diastolic blood pressure of 105 or higher
- altered mental status
- meningeal signs
- suspicion for intracranial process requiring further investigation
- known allergy to prochlorperazine
- the use of ergotamines, antiemetics, antipsychotics or sedatives in the previous 24 hours of study entry.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Buccal Prochlorperazine Prochlorperazine Experimental arm of two buccally absorbable prochlorperazine tablets (6 mg) plus 2 cc IV saline Intravenous Prochlorperazine Prochlorperazine Accepted Standard of care receiving 10 mg (2 cc) of intravenous prochlorperazine plus two saccharin absorbable placebo tablets.
- Primary Outcome Measures
Name Time Method Change in median pian VAS score From Time 0 (baseline) to Time 60 minutes after administration of medication Primary end point will be a detectable difference in the median pain VAS score recorded from Time 0 (baseline) to Time 60 minutes (conclusion of the study) for each of the two groups.
- Secondary Outcome Measures
Name Time Method Change in median sedation VAS scores From Time 0 (baseline) to Time 60 minutes after administration of medication Secondary endpoints will include a detectable difference in median sedation VAS scale from Time 0 (baseline) to Time 60 minutes (conclusion of the study for each of the two groups.
Rescue Medication At the conclusion of the study (60 minutes) Comparison between groups for the need for rescue medication as determined by the primary care provider.
Change in median nausea VAS scores From Time 0 (baseline) to Time 60 minutes after administration of medication Secondary endpoints will include a detectable difference in median nausea VAS scale from Time 0 (baseline) to Time 60 minutes (conclusion of the study for each of the two groups.
Follow-up for persistence or recurrence of headache 24 -48 hours Using a Pain Relief Scale, subjects will be contacted by telephone at 24 - 48 hours after the conclusion of the study and asked to rate their current headache pain.
Trial Locations
- Locations (1)
Harbor-UCLA Medical Center
🇺🇸Torrance, California, United States